Show simple item record

dc.contributor.authorHalle, Mari Kyllesø
dc.contributor.authorTangen, Ingvild Løberg
dc.contributor.authorBerg, Hege Fredriksen
dc.contributor.authorHoivik, Erling A
dc.contributor.authorMauland, Karen Klepsland
dc.contributor.authorKusonmano, Kanthida
dc.contributor.authorBerg, Anna
dc.contributor.authorHurtado, Antoni
dc.contributor.authorKalland, Karl-Henning
dc.contributor.authorØyan, Anne Margrete
dc.contributor.authorStefansson, Ingunn
dc.contributor.authorVintermyr, Olav Karsten
dc.contributor.authorWerner, Henrica Maria Johanna
dc.contributor.authorHaldorsen, Ingfrid S.
dc.contributor.authorTrovik, Jone
dc.contributor.authorSalvesen, Helga Birgitte
dc.contributor.authorKrakstad, Camilla
dc.date.accessioned2017-12-05T14:28:05Z
dc.date.available2017-12-05T14:28:05Z
dc.date.issued2017-11-23
dc.identifier.issn0007-0920
dc.identifier.urihttp://hdl.handle.net/1956/16983
dc.description.abstract<p>Background: Despite successful implementation of drugs targeting the human epidermal growth factor receptor 2 (HER2) receptor in breast and gastric cancers, the potential of HER2 as a therapeutic target in other cancers has been less studied, including endometrial cancer. We investigated expression levels of HER2 (ERBB2) in a large cohort of endometrial cancer lesions, also including complex atypical hyperplasia and metastatic lesions.</p> <p>Methods: 67 precursor lesions, 790 primary endometrial cancers and 383 metastatic lesions were investigated for HER2 expression in relation to clinicopathologic features and outcome. Protein levels were assessed by immunohistochemistry (using the HercepTest and staining index (SI) criteria), mRNA levels by microarrays and amplification status by chromogenic in situ hybridisation.</p> <p>Results: High HER2 protein levels were significantly associated with features of aggressive disease and increased mRNA ERBB2 levels. HER2 expression defined by the SI proved to be a better predictor of survival compared with the HercepTest. A discordant HER2 expression pattern between paired primary and metastatic lesions was detected, revealing substantial reduction in HER2 expression from primary to metastatic disease.</p> <p>Conclusions: Loss of HER2 expression is common in metastatic endometrial cancer lesions and assessment of HER2 levels in the metastatic lesions may be important to define the potential benefit of anti-HER2 treatments in endometrial cancer patients.</p>eng
dc.language.isoengeng
dc.publisherNature Publishing Groupeng
dc.relation.ispartof<a href=" http://hdl.handle.net/1956/16984" target="blank"> Molecular alterations suggesting new treatment strategies in uterine carcinomas</a>
dc.rightsAttribution-NonCommercial-NoDerivatives CC BY-NC-NDeng
dc.subjectHER2 testingeng
dc.subjectHercepTesteng
dc.subjectendometrial carcinomaeng
dc.subjectprognostic biomarkerseng
dc.subjectchromogenic in situ hybridisationeng
dc.subjectmetastatic biopsieseng
dc.subjectantibody-drugs conjugateeng
dc.subjecttrastuzumabeng
dc.titleHER2 expression patterns in paired primary and metastatic endometrial cancer lesionseng
dc.typeJournal articleeng
dc.rights.holderCopyright 2017 Cancer Research UK.eng
dc.type.versionpublishedVersioneng
bora.peerreviewedPeer reviewedeng
bora.journalTitleBritish Journal of Cancereng
bibo.eissn1532-1827eng
dc.identifier.doi10.1038/bjc.2017.422eng
dc.rights.termsUnder embargo until: 2018-11-24


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record